<DOC>
	<DOCNO>NCT03099135</DOCNO>
	<brief_summary>The main purpose study evaluate durability Sustained virologic response ( SVR ) participant achieve SVR last post-therapy visit parent study ( LPVPS ) NCT Numbers NCT02569710 NCT02765490 .</brief_summary>
	<brief_title>A Long Term Follow-up Study Participants Treated Preceding Phase 2 3 Study With Regimen Containing Odalasvir AL-335 With Without Simeprevir Treatment Hepatitis C Virus ( HCV ) Infection</brief_title>
	<detailed_description>This multicentre study provide study treatment collect follow-up data 3 year assess long term durability SVR achieve one parent study [ phase 2 3 AL-335 Odalasvir ( ODV ) without Simeprevir ( SMV ] . In addition participant fail achieve SVR parent study enrol assess presence resistance associate substitution ( RAS ) persistance time . It expect vast majority approximately 250 participant enrol study . Safety parameter Liver disease status assess participant time .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Participant randomize regimen contain Odalasvir ( ODV ) AL335 without Simeprevir precede Phase 2 Phase 3 study ( parent study ) Participant receive least 1 dose ODV AL335 without SMV parent study Participant complete last posttherapy followup visit parent study ( LPVPS ) pass screen period 6 + 3 month LPVPS Participant sign informed consent form ( ICF ) indicate understands purpose procedure require study willing participate study Participant currently enrol plan enroll another study investigational drug ( include investigational vaccine ) invasive investigational medical device LPVPS Visit 6 present study ( 36 month ( +/ ) 4 week LPVPS parent study ) Participant receive antiviral immunomodulating treatment , include therapeutic vaccine , HCV infection LPVPS screen visit present study , plan receive treatment period followup study Participant able adhere requirement followup study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>